CASI Pharmaceuticals, Inc. (NASDAQ:CASI) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by $0.01, Bloomberg Earnings reports.

CASI Pharmaceuticals (NASDAQ CASI) opened at 0.99 on Tuesday. The firm’s market cap is $59.59 million. The firm has a 50-day moving average of $1.05 and a 200 day moving average of $1.17. CASI Pharmaceuticals has a 52-week low of $0.91 and a 52-week high of $1.76.

An institutional investor recently raised its position in CASI Pharmaceuticals stock. Renaissance Technologies LLC raised its stake in shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) by 103.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,800 shares of the biotechnology company’s stock after buying an additional 63,500 shares during the period. Renaissance Technologies LLC owned approximately 0.21% of CASI Pharmaceuticals worth $144,000 as of its most recent SEC filing. 3.90% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “CASI Pharmaceuticals, Inc. (CASI) Issues Quarterly Earnings Results” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at

Several research analysts have issued reports on the stock. Maxim Group set a $4.00 price target on shares of CASI Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday. ValuEngine upgraded shares of CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Earnings History for CASI Pharmaceuticals (NASDAQ:CASI)

Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.